iPSCs: A Preclinical Drug Research Tool for Neurological Disorders
The development and commercialization of new drugs is an articulated, lengthy, and very expensive process that proceeds through several steps, starting from target identification, screening new leading compounds for testing in preclinical studies, and subsequently in clinical trials to reach the fin...
Main Authors: | Gabriele Bonaventura, Rosario Iemmolo, Giuseppe Antonino Attaguile, Valentina La Cognata, Brigida Sabrina Pistone, Giuseppe Raudino, Velia D’Agata, Giuseppina Cantarella, Maria Luisa Barcellona, Sebastiano Cavallaro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4596 |
Similar Items
-
Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs
by: Yi Yang, et al.
Published: (2018-01-01) -
The safety and effectiveness of genetically corrected iPSCs derived from β-thalassaemia patients in nonmyeloablative β-thalassaemic mice
by: Yexing Xian, et al.
Published: (2020-07-01) -
iPSCs are safe!
by: Hualong Yan, et al.
Published: (2017-05-01) -
iPSCs in Modeling and Therapy of Osteoarthritis
by: Maria Csobonyeiova, et al.
Published: (2021-02-01) -
Osteochondral Tissue Chip Derived From iPSCs: Modeling OA Pathologies and Testing Drugs
by: Zixuan Lin, et al.
Published: (2019-12-01)